MCID: NRN001
MIFTS: 53

Neuroendocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Neuroendocrine Carcinoma

MalaCards integrated aliases for Neuroendocrine Carcinoma:

Name: Neuroendocrine Carcinoma 12 15
Carcinoma, Neuroendocrine 45
Carcinoma Neuroendocrine 56
Neuroendocrine Cancer 77

Classifications:



External Ids:

Disease Ontology 12 DOID:1800
MeSH 45 D018278
NCIt 51 C3773
SNOMED-CT 69 55937004
UMLS 74 C0206695

Summaries for Neuroendocrine Carcinoma

Disease Ontology : 12 A carcinoma that derives from neuroendocrine cells.

MalaCards based summary : Neuroendocrine Carcinoma, also known as carcinoma, neuroendocrine, is related to pulmonary large cell neuroendocrine carcinoma and primary hepatic neuroendocrine carcinoma. An important gene associated with Neuroendocrine Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Cytoskeletal Signaling and Neuroscience. The drugs Octreotide and Axitinib have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and breast, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 77 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Carcinoma

Diseases related to Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 34.2 CHGA ENO2 SYP
2 primary hepatic neuroendocrine carcinoma 34.1 CHGA SYP
3 urinary bladder small cell neuroendocrine carcinoma 33.9 CHGA ENO2 SYP
4 ovarian large-cell neuroendocrine carcinoma 33.6 CHGA KRT20 NCAM1 SYP
5 large cell neuroendocrine carcinoma 32.1 ASCL1 CHGA ENO2 KIT KRT20 KRT7
6 pancreatic endocrine carcinoma 31.7 NCAM1 SST SYP
7 merkel cell carcinoma 31.6 CHGA ENO2 KIT KRT20 KRT7 NCAM1
8 gallbladder small cell carcinoma 31.5 CHGA ENO2 KRT7 NCAM1 SYP
9 small cell carcinoma of the bladder 31.4 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
10 sinonasal undifferentiated carcinoma 30.5 ENO2 SYP
11 carcinosarcoma 30.5 KIT KRT7 PTEN
12 multiple endocrine neoplasia, type i 30.4 CHGA SST SYP
13 malignant sertoli cell tumor 30.3 ENO2 SYP
14 bladder adenocarcinoma 30.2 KRT20 KRT7
15 adenosquamous carcinoma 30.2 KIT KRT7 NKX2-1
16 eyelid carcinoma 30.2 KRT20 KRT7
17 papilloma 30.1 KRT20 KRT7 PTEN
18 olfactory neuroblastoma 30.1 CHGA ENO2 SYP
19 spindle cell carcinoma 30.0 CDH1 KRT7 SYP
20 teratoma 30.0 ENO2 KIT KRT7 NKX2-1 SYP
21 tubular adenocarcinoma 30.0 CDH1 CHGA KRT20 SYP
22 cystadenoma 30.0 CHGA KRT20 KRT7 SYP
23 lung cancer susceptibility 3 30.0 CDH1 KRT20 KRT7 NKX2-1
24 suppression of tumorigenicity 12 29.9 CDH1 CHGA PTEN
25 paraganglioma 29.8 CHGA ENO2 SST SYP
26 uterine carcinosarcoma 29.7 CDH1 KIT PTEN
27 carcinoid syndrome 29.7 CALCA CHGA ENO2 SST SYP
28 hemangioma 29.7 CHGA ENO2 NKX2-1 PTEN SYP
29 mucinous adenocarcinoma 29.7 KRT20 KRT7 NKX2-1
30 large cell carcinoma 29.7 CHGA ENO2 KRT7 NCAM1 NKX2-1 SYP
31 pancreatic serous cystadenoma 29.6 CHGA KRT7 NCAM1 SYP
32 cystic teratoma 29.6 ENO2 KRT20 KRT7 NKX2-1 SYP
33 signet ring cell adenocarcinoma 29.5 CDH1 CHGA KRT20 KRT7
34 gastric squamous cell carcinoma 29.4 CHGA ENO2 KRT7 NCAM1 SYP
35 endometrial small cell carcinoma 29.4 ENO2 KIT NCAM1 PDGFRA SYP
36 constipation 29.3 CALCA KIT SST
37 renal cell carcinoma, nonpapillary 29.2 CDH1 KIT KRT20 KRT7 NKX2-1
38 gastrointestinal stromal tumor 29.2 CHGA ENO2 KIT NCAM1 PDGFRA PTEN
39 thyroid carcinoma, familial medullary 29.0 CALCA CHGA ENO2 NKX2-1 SST
40 gastric adenocarcinoma 28.9 CDH1 CHGA KIT KRT20 KRT7 PTEN
41 small cell cancer of the lung 28.8 ASCL1 CALCA CHGA ENO2 KIT KRT18
42 transitional cell carcinoma 28.7 CDH1 ENO2 KRT18 KRT20 KRT7 PTEN
43 papillary carcinoma 28.6 CALCA CDH1 KRT20 KRT7 NKX2-1
44 islet cell tumor 28.6 CALCA CHGA SST
45 cholangiocarcinoma 28.6 CDH1 KRT18 KRT20 KRT7 NCAM1 PTEN
46 small cell carcinoma 28.4 CALCA CHGA ENO2 KIT KRT20 KRT7
47 thyroid cancer 28.3 CALCA CDH1 CHGA KIT NKX2-1 PTEN
48 pheochromocytoma 28.1 ASCL1 CALCA CHGA ENO2 NCAM1 SST
49 neuroendocrine tumor 27.8 ASCL1 CALCA CHGA ENO2 KRT20 KRT7
50 lung cancer 27.7 ASCL1 CDH1 CHGA ENO2 KIT KRT18

Graphical network of the top 20 diseases related to Neuroendocrine Carcinoma:



Diseases related to Neuroendocrine Carcinoma

Symptoms & Phenotypes for Neuroendocrine Carcinoma

MGI Mouse Phenotypes related to Neuroendocrine Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 ASCL1 ENO2 KIT NCAM1 NKX2-1 PDGFRA
2 growth/size/body region MP:0005378 9.96 ASCL1 CDH1 CHGA ENO2 KIT KRT18
3 nervous system MP:0003631 9.85 ASCL1 CHGA ENO2 KIT NCAM1 NKX2-1
4 no phenotypic analysis MP:0003012 9.5 ASCL1 CDH1 CHGA KIT NKX2-1 PDGFRA
5 normal MP:0002873 9.23 ASCL1 CDH1 KIT NKX2-1 PDGFRA PTEN

Drugs & Therapeutics for Neuroendocrine Carcinoma

Drugs for Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 2, Phase 3,Phase 1 83150-76-9 6400441 383414
2
Axitinib Approved, Investigational Phase 2, Phase 3 319460-85-0 6450551
3
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
4
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
5 Radiopharmaceuticals Phase 3,Phase 2,Phase 1
6 3-Iodobenzylguanidine Phase 3
7 Gastrointestinal Agents Phase 2, Phase 3,Phase 1,Not Applicable
8 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1
9 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable
10 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
11 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1,Not Applicable
12 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Not Applicable
13 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
14 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
15
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
16
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
17
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
18
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177 70789204
19
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
20
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
21
Cisplatin Approved Phase 2,Phase 1 15663-27-1 441203 84093 2767
22
Gemcitabine Approved Phase 2 95058-81-4 60750
23
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
24
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
25
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
26
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
27
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
28
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
29
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
30
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
31
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
32
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
33
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
34
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
35
Melphalan Approved Phase 2 148-82-3 460612 4053
36
Pasireotide Approved Phase 2,Phase 1 396091-73-9 9941444
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
39
Salmon Calcitonin Approved, Investigational Phase 2,Phase 1,Early Phase 1,Not Applicable 47931-85-1 16129616
40
Iodine Approved, Investigational Phase 2 7553-56-2 807
41
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
42
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
43
lanreotide Approved Phase 2 108736-35-2
44
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
45
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
46
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
47
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
48
Pancrelipase Approved, Investigational Phase 2,Phase 1,Not Applicable 53608-75-6
49
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
50
nivolumab Approved Phase 2,Phase 1 946414-94-4

Interventional clinical trials:

(show top 50) (show all 259)
# Name Status NCT ID Phase Drugs
1 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Recruiting NCT01744249 Phase 2, Phase 3 Axitinib;Sandostatin LAR;Placebo
5 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Recruiting NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
6 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Recruiting NCT03783078 Phase 3 Pembrolizumab (MK-3475)
7 Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer Recruiting NCT03712605 Phase 3
8 Adjuvant Avelumab in Merkel Cell Cancer Recruiting NCT03271372 Phase 3 Avelumab
9 Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Active, not recruiting NCT01298323 Phase 3 Vandetanib
10 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Active, not recruiting NCT00704730 Phase 3 XL184;Placebo
11 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
12 Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma Unknown status NCT02943798 Phase 2 etoposide plus carboplatin;Paclitaxel plus carboplatin
13 Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Unknown status NCT02687958 Phase 2 Everolimus
14 68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors Unknown status NCT01879657 Phase 1, Phase 2 68Ga-DOTATATE PET scan
15 Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors Unknown status NCT00178698 Phase 2 Cisplatin, Gemcitabine, Interferon-a
16 Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors Unknown status NCT01203306 Phase 2 bevacizumab + octreotide LAR + capecitabine
17 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
18 The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Unknown status NCT01739634 Phase 1, Phase 2 CASAD
19 Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients Completed NCT02457273 Phase 2 TLC 388
20 Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma Completed NCT00607113 Phase 2 Avastin;RAD001
21 Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00388063 Phase 2 Atiprimod
22 Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Completed NCT00663429 Phase 2 Atiprimod
23 Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma Completed NCT00193531 Phase 2 Paclitaxel;Carboplatin;Etoposide
24 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
25 Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Completed NCT01121939 Phase 2 Bevacizumab;Pertuzumab;Sandostatin LAR® Depot
26 Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract Completed NCT00353015 Phase 2 Cisplatin;Irinotecan
27 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
28 S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
29 Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00780663 Phase 2 Quarfloxin
30 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
31 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
32 Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients Completed NCT01873248 Phase 1, Phase 2 68Ga-DOTATATE
33 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors Completed NCT00953394 Phase 2 continuous 5 fluouracil infusion plus long-acting octreotide
34 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
35 IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC Completed NCT01480986 Phase 2 Irinotecan combined with cisplatin, octreotide lar
36 S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Completed NCT00068783 Phase 2 imatinib mesylate
37 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
38 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
39 TheraSphere for the Treatment of Liver Metastases Completed NCT00511862 Phase 2
40 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
41 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
42 DOTA-TOC in Metastasized Neuroendocrine Tumors Completed NCT00978211 Phase 2 DOTA-TOC Treatment
43 Oblimersen in Treating Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
44 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
45 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
46 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
47 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
48 SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer Completed NCT01625520 Phase 2 SOM230 alone or in combination with RAD001.
49 Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer Completed NCT01270321 Phase 2 Everolimus;Pasireotide;Everolimus and Pasireotide
50 A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Completed NCT00358956 Phase 2 ZD6474 (vandetanib)

Search NIH Clinical Center for Neuroendocrine Carcinoma

Cochrane evidence based reviews: carcinoma, neuroendocrine

Genetic Tests for Neuroendocrine Carcinoma

Anatomical Context for Neuroendocrine Carcinoma

MalaCards organs/tissues related to Neuroendocrine Carcinoma:

42
Thyroid, Lung, Breast, Cervix, Skin, Liver, Pancreas

Publications for Neuroendocrine Carcinoma

Articles related to Neuroendocrine Carcinoma:

(show top 50) (show all 1657)
# Title Authors Year
1
Villous Adenoma Arising in the Native Bladder Mucosa and the Upper Urinary Tract With Coexisting Neuroendocrine Carcinoma Following Augmentation Cystoplasty. ( 30701999 )
2019
2
Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. ( 30828454 )
2019
3
Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. ( 30107896 )
2019
4
Smear cytological features of large cell neuroendocrine carcinoma of the uterine cervix in pregnancy: A case report and review of the literature. ( 30461217 )
2019
5
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel KIF5B-ALK Fusion Oncokinase. ( 30591488 )
2019
6
Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab. ( 30642453 )
2019
7
Large cell neuroendocrine carcinoma of the uterine cervix. ( 30642849 )
2019
8
Pure large cell neuroendocrine carcinoma of ovary: A rare clinical entity. ( 30658028 )
2019
9
CD146 promotes migration and proliferation in pulmonary large cell neuroendocrine carcinoma cell lines. ( 30675274 )
2019
10
Management of brain metastases from large cell neuroendocrine carcinoma of the lung: improved outcomes with radiosurgery. ( 30732516 )
2019
11
Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. ( 30734490 )
2019
12
Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. ( 30793508 )
2019
13
Large Cell Neuroendocrine Carcinoma Shares Similarity with Small Cell Carcinoma on the Basis of Clinical and Pathological Features. ( 30818166 )
2019
14
Stereotactic body radiation therapy for pulmonary large cell neuroendocrine carcinoma: a case report. ( 30863102 )
2019
15
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). ( 30885341 )
2019
16
Concurrent Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) and Squamous Cell Carcinoma of the Skin on the Right Ear Helix. ( 29607680 )
2019
17
BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. ( 30144031 )
2019
18
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. ( 30635447 )
2019
19
Can a High-grade Neuroendocrine Carcinoma be Functional? ( 30638597 )
2019
20
Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder. ( 30661049 )
2019
21
Hepatobiliary and Pancreatic: A procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma. ( 30663800 )
2019
22
PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type of the uterine cervix. ( 30667073 )
2019
23
Collision carcinoma of squamous cell carcinoma and small cell neuroendocrine carcinoma of the larynx: A case report and review of the literature. ( 30705902 )
2019
24
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. ( 30713600 )
2019
25
A competing-risks nomogram and recursive partitioning analysis for cause-specific mortality in patients with esophageal neuroendocrine carcinoma. ( 30715226 )
2019
26
Neuroendocrine carcinoma of gallbladder: a case series and literature review. ( 30717775 )
2019
27
Lymph node involvement and the surgical treatment of thymic epithelial and neuroendocrine carcinoma. ( 30721691 )
2019
28
Small-cell neuroendocrine carcinoma of the uterine cervix with pancreatic metastasis: a case report and a review of the literature. ( 30744460 )
2019
29
Early-stage Neuroendocrine Carcinoma of the Esophagus Observed with Annual Endoscopy for Three Years: A Case Report. ( 30799355 )
2019
30
A unique case of ectopic Cushing's syndrome from a thymic neuroendocrine carcinoma. ( 30802210 )
2019
31
Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma. Retrospective analysis. ( 30843182 )
2019
32
Metastatic neuroendocrine carcinoma presenting as multifocal liver lesions with elevated alpha-fetoprotein. ( 30847183 )
2019
33
Primary Hepatic Neuroendocrine Carcinoma Treated with Doxorubicin and Cyclophosphamide in a Dog. ( 30870605 )
2019
34
Primary poorly differentiated small cell type neuroendocrine carcinoma of the hypopharynx. ( 30881014 )
2019
35
Can surgical treatment be justified for neuroendocrine carcinoma of the gallbladder? ( 30882701 )
2019
36
Clinicopathologic Features and Surgical Outcomes of Neuroendocrine Carcinoma of the Gallbladder. ( 30888678 )
2019
37
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. ( 30898132 )
2019
38
Mixed neuroendocrine-non-neuroendocrine carcinoma of gallbladder: case report. ( 30902091 )
2019
39
Epstein-Barr Virus-Positive Large Cell Neuroendocrine Carcinoma of the Nasopharynx: Report of a Case with Complete Clinical and Radiological Response After Combined Chemoradiotherapy. ( 29302900 )
2018
40
Metastatic laryngeal large cell neuroendocrine carcinoma: A rare case of presentation and extreme tumor burden. ( 29194700 )
2018
41
Large-cell neuroendocrine carcinoma arising in the endometrium: A case report. ( 29564132 )
2018
42
Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome Associated with Neuroendocrine Carcinoma of the Oropharynx. ( 29093415 )
2018
43
Esophageal Large-Cell Neuroendocrine Carcinoma with Inconsistent Response to Treatment in the Primary and Metastatic Lesions. ( 29928189 )
2018
44
Large-cell neuroendocrine carcinoma arising from a gastritis cystica polyposa. ( 29305822 )
2018
45
An extremely rare case of Epstein-Barr virus-associated gastric carcinoma with differentiation to neuroendocrine carcinoma. ( 29244230 )
2018
46
Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration. ( 29271588 )
2018
47
Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? ( 29413048 )
2018
48
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
49
Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. ( 28940307 )
2018
50
Large cell neuroendocrine carcinoma of the endometrium: A case report and literature review. ( 29458887 )
2018

Variations for Neuroendocrine Carcinoma

Copy number variations for Neuroendocrine Carcinoma from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss C10orf57 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication C16orf45 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication C16orf63 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication KIAA0430 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain HER-2/neu Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication C9orf62 Neuroendocrine carcinoma

Expression for Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Neuroendocrine Carcinoma.

Pathways for Neuroendocrine Carcinoma

GO Terms for Neuroendocrine Carcinoma

Cellular components related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic side of plasma membrane GO:0009898 8.8 CDH1 KIT PTEN

Biological processes related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 9.63 KRT18 KRT20 KRT7
2 negative regulation of apoptotic process GO:0043066 9.5 ASCL1 KRT18 PTEN
3 mast cell degranulation GO:0043303 9.43 CHGA KIT
4 positive regulation of phospholipase C activity GO:0010863 9.4 KIT PDGFRA
5 Leydig cell differentiation GO:0033327 9.37 NKX2-1 PDGFRA
6 forebrain neuron differentiation GO:0021879 9.26 ASCL1 NKX2-1
7 mast cell chemotaxis GO:0002551 9.16 CHGA KIT
8 cerebral cortex GABAergic interneuron differentiation GO:0021892 8.96 ASCL1 NKX2-1
9 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Molecular functions related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 KIT NCAM1 PDGFRA
2 platelet-derived growth factor receptor binding GO:0005161 8.62 PDGFRA PTEN

Sources for Neuroendocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....